clinical design

Capturing data which is accurate and timely is one of the critical elements that predicates the success of a clinical trial.

Cedars Sinai and the University of Michigan share their predictions for the coming changes to clinical trials

The following predictions were based on interviews with range of professionals in the pharma and biotech space. To hear from these thought leaders and more go to the Pharma Show Podca...

Chris Jennison, Professor of Statistics at the University of Bath, joins Pharma IQ to discuss the merits of Sequential Monitoring and Adaptive Design. Pharma IQ: Chris, welcome, I’m pleased...

Chrissie Fletcher, Director and Head of International Biostatistics at Amgen, talks to Helen Winsor from Pharma IQ, about innovation in clinical design, analysis and reporting. Fletcher disc...

In this interview Dr. Thomas Jaki, Lecturer from Lancaster University and expert in the estimation of pharmacokinetic (PK) parameters, speaks to Helen Winsor from Pharma IQ. He outlines the key i...

In this interview Martin Jenkins, Senior Statistician at AstraZeneca, speaks to Andrea Charles from Pharma IQ, about exploring the potential uses of biomarkers to enhance early clinical development,...

Clinical trials may be one of the most fundamental parts of drug development work carried out in the pharmaceutical industry, but they still remain a complicated area for pharma companies to address....

When carried out well, adaptive trials not only provide evidence of safety and efficacy more quickly, but also allow you to assess that evidence and get answers earlier. In this inter...

 When considering the key challenges that new drugs face on their route to widespread use, clinical trials are undoubtedly one of the most vital. The results of such assessments play a key role...